BioCentury
ARTICLE | Finance

Goldfinch’s $100M round sets up Third Rock company to advance kidney disease therapies

July 1, 2020 1:51 AM UTC

With $100 million in series B funding, Goldfinch Bio Inc. aims to move its second kidney disease therapy into the clinic and begin Phase II testing of its lead candidate.

Eventide Asset Management led the deal, which is the 47th megaround of 2020 (see “Data Bytes”)...